OXB Oxford Biomedica plc

LSE · GB · Healthcare · Biotechnology · oxb.com
6.755USD513.00 GBp · LSE-2.66%Mkt Cap: 820.50M USDP/E: —

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system wh…

Institutional holders10 on file

Key Statistics

Company
Market Cap820.50M USD
Enterprise Value949.75M USD
Revenue (TTM)230.93M USD
Gross Profit86.89M USD
Net Income (TTM)-39.67M USD
Revenue/Share1.93 USD
Last Price6.755 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.0K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BDFBVT43
Valuation
P/E (Trailing)—
P/E (Forward)-50.57
PEG—
EV/EBITDA-31.74
EV/Revenue4.11
P/S3.55
P/B10.69
EPS (TTM)-0.42 USD
EPS (Forward)-0.13 USD
52W Range
5.53117% of range12.67
52W High12.67 USD
52W Low5.531 USD
Profitability
Gross Margin39.10%
Oper. Margin-16.52%
EBITDA Margin-12.96%
Profit Margin-17.85%
ROE-32.98%
ROA-9.25%
ROIC-22.18%
ROCE-13.65%
Growth
Revenue Growth9.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF667.64K USD
CapEx (TTM)6.27M USD
FCF Margin-14.78%
FCF Yield-4.16%
Net Debt109.77M USD
Net Debt/EBITDA-3.67
Net Debt/FCF—
Balance Sheet
Debt/Equity1.62
Current Ratio2.21
Quick Ratio1.76
Book Value/Sh0.63 USD
Cash/Share0.82 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:50
Split DateMay 30, 2018
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.081 USD
Upside (mean)+34.4%
Target Range6.690 USD – 11.85 USD
6.690+34.4% to mean11.85
# Analysts8
Ownership
Shares Out.121.46M
Float60.97M
Insiders20.50%
Institutions65.72%
Technical
SMA 506.729 (+0.4%)
SMA 2007.655 (-11.8%)
Beta1.07
S&P 52W Chg12.08%
Avg Vol (30d)234.06K
Avg Vol (10d)294.02K
Technical Indicators
RSI (14)42.5
MACD1.9703
MACD Signal6.2384
MACD Hist.-4.2681
BB Upper7.400 USD
BB Middle7.066 USD
BB Lower6.731 USD
BB Width9.47%
ATR (14)0.3413 USD
Vol Ratio (20d)1.10x

About Oxford Biomedica (LON: OXB)

›

Oxford Biomedica (LON: OXB) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,017 employees.

The shares were at 513.00 GBp on 19 November 2026, down 16.4% over 52 weeks. Its 52-week range is 420.00 GBp to 962.00 GBp: the price is 46.7% below the high and 22.1% above the low.

Its market capitalisation is 623.08M GBP.

Oxford Biomedica reports return on equity of -33.0%, an operating margin of -16.5% and revenue up 9.0% year over year.

Its debt exceeds its cash by 83.36M GBP, a debt-to-equity ratio of 1.62. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 689.63 GBp is 34.4% above the current price. The next earnings report is expected on 25 March 2027.